

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): June 13, 2019**

**Solid Biosciences Inc.**  
(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-38360**  
(Commission  
File Number)

**90-0943402**  
(IRS Employer  
Identification No.)

**141 Portland Street, Fifth Floor  
Cambridge, MA 02139**  
(Address of Principal Executive Offices) (Zip Code)

**Registrant's telephone number, including area code: (617) 337-4680**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
<b>Common Stock \$0.001 par value per share</b>	<b>SLDB</b>	<b>The Nasdaq Global Select Market</b>

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.07 Submission of Matters to a Vote of Security Holders**

Solid Biosciences Inc. (the “Company”) held its Annual Meeting of Stockholders on June 13, 2019. The following is a summary of the matters voted on at that meeting.

1. The Company’s stockholders elected Robert Huffines, Adam Koppel, Sukumar Nagendran and Rajeev Shah as Class I directors to serve until the 2022 Annual Meeting of Stockholders, each director to hold office until his successor has been duly appointed and qualified. The results of the stockholders’ vote with respect to the election of such Class I directors were as follows:

	Votes For	Votes Against	Votes Abstain	Broker Non-Votes
Robert Huffines	22,809,674	570,245	21,814	4,009,677
Adam Koppel	22,969,745	410,035	21,953	4,009,677
Sukumar Nagendran	23,271,865	108,185	21,683	4,009,677
Rajeev Shah	22,966,097	414,003	21,633	4,009,677

2. The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year. The results of the stockholders’ vote with respect to such ratification were as follows:

Votes For	Votes Against	Votes Abstaining
27,333,897	45,295	32,218

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SOLID BIOSCIENCES INC.

Date: June 14, 2019

By: /s/ Jennifer Ziolkowski

Name: Jennifer Ziolkowski

Title: Chief Financial Officer